Zepbound vs. Wegovy: Which Is Right for You?

Two brands, one decision

Walk into any conversation about weight-loss medication and you will hear the two names traded as if they were interchangeable: Zepbound and Wegovy. They are not the same drug, and — since the first trial that put them in the same room — they no longer post the same result. But "which is right for you" does not end at the bigger number. For a mother it is also written in side effects, in the monthly cost, in whether you are planning a pregnancy, and in a birth-control warning that applies to one of these drugs and not the other.

Zepbound is tirzepatide. Wegovy is semaglutide. The same two molecules are sold as Mounjaro and Ozempic for type 2 diabetes — same medicine, different label, different indication. When a friend says her sister is "on Ozempic for weight loss," she means the semaglutide family; the weight-loss brand is Wegovy.

One thing most comparisons still get wrong: these are no longer two once-weekly injections. Zepbound is weekly and injected only — pens or vials, 2.5 mg to 15 mg⁷. Wegovy comes both ways: the weekly pen, and a tablet taken once daily on an empty stomach in the morning, in 1.5, 4, 9 and 25 mg⁸. If needles are what is stopping you, that may settle this before any efficacy number does.

The head-to-head, at last

For years the comparison leaned on separate trials run at different times on different people — a statistician's nightmare and a marketer's playground. That changed with SURMOUNT-5: 751 adults with obesity and no diabetes, randomized directly to one drug or the other at the maximum tolerated dose, over 72 weeks. Least-squares mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide, with waist circumference favoring tirzepatide too, −18.4 cm against −13.0 cm¹.

It rhymes with each drug's own placebo-controlled trial — and those deserve quoting with their comparison arms attached, because a percentage with nothing beside it is not information. In STEP 1, semaglutide produced a mean −14.9% over 68 weeks against −2.4% on placebo². In SURMOUNT-1, tirzepatide at the top 15 mg dose reached −20.9% against −3.1% on placebo³.

The responder figures need the same handling, because they get repeated without their denominator. In STEP 1, 86.4% of people on semaglutide lost at least 5% of their weight, 69.1% at least 10%, and 50.5% at least 15% — percentages calculated on the 1,212 participants who had a week-68 weight, not on the 1,306 randomized to semaglutide². A modest gap, honestly reported. But it is still a headline about the people who stayed.

And here is the caveat no headline prints: "more on average" is a fact about groups, not about you. Plenty of women lose a great deal on semaglutide, tolerate it far better, or simply pay less for it.

How the choice actually gets made

There is a small, useful piece of research on the decision itself rather than on the drugs. A team in Dublin put the same question to 39 adults living with obesity — 88.5% of them women, aged 18 to 70 — three different ways: semi-structured interviews, a photovoice study, and focus groups⁹.

Tirzepatide came first in all three, chosen for the weight-loss numbers. Semaglutide came second, and the reasons are the interesting part: established efficacy, yes, but also familiarity and perceived safety — the runner-up preferred for being the devil people already knew. Across the study, what shaped choices was anticipated efficacy and how well a drug had been explained, with safety perceptions reliably cooling enthusiasm for whatever had otherwise ranked first.

Side effects: the same family, mostly at dose changes

Both drugs work through GLP-1 signaling; Zepbound adds a second gut hormone, GIP. Because the machinery overlaps, the side-effect profile does too. Gastrointestinal effects — nausea, diarrhea, constipation, vomiting — are the most common with both, most are mild to moderate, and they cluster during the weeks you are increasing the dose rather than at a settled maintenance dose¹.

There is no reliably "gentle" option here. Tolerance is individual, and the variable that matters more than the brand is the program: one that titrates slowly, checks in when the nausea spikes, and is willing to switch molecules if the first one does not sit well. A brand name cannot do any of that. A clinician can.

Staying there: the maintenance question a mother should ask first

Weight loss that reverses the moment you stop is not the goal — and this is where a mother's-eye view earns its keep, because motherhood comes with planned pauses. Both drugs are studied as ongoing treatments, not courses you finish. When semaglutide was swapped for placebo in STEP 4, those participants regained 6.9% over 48 weeks while the ones who stayed on it lost a further 7.9%⁴. In SURMOUNT-4, continuing tirzepatide took off another 5.5% while switching to placebo put 14.0% back on⁵.

So if there is any chance you will pause treatment, "what happens when I stop, and how do I restart" is a more useful question than "which number is bigger." We walk through that arc in coming off a GLP-1 and the rebound question.

Cost and access

Resist any article — including an earlier version of this one — that tells you flatly which of these is cheaper. It has not been a stable fact. Both manufacturers now sell direct to self-pay patients at dose-tiered prices that have been cut, re-cut and time-limited repeatedly, and the cheapest option differs at a starting dose, at a maintenance dose, and again if you can take the tablet.

What is durable is the trade-off underneath, and a US cost-effectiveness analysis built directly on the SURMOUNT-5 head-to-head examines it⁶. What decides it for most mothers is what your plan covers, at what dose, and what leaves your account each month — a figure that only climbs as the dose does. Read the true cost as the dose climbs, then check both manufacturers' own self-pay pages on the day you decide. Note too that neither brand is available as a low-cost compounded vial; we weigh that separate question in compounded vs. brand on a family budget. If you want the brand pens without giving up a same-platform compounded option, Eve lists Ozempic, Wegovy and Mounjaro alongside a flat $195/mo compounded alternative on one account — though its brand pricing runs well above either manufacturer's own self-pay rate, so price both routes yourself before you decide. OnlyRx does the same bridging in all 50 states, plus a needle-free oral tablet on either molecule. Teleios Health skips the brand question entirely at a flat $99/mo compounded, well under either manufacturer's self-pay floor.

The mother-specific differences a brand comparison skips

Two facts belong in this decision that a straight efficacy chart leaves out entirely, and on both of them the two labels say genuinely different things.

• Birth control. The Zepbound label warns that oral hormonal contraceptives may become less effective, instructing clinicians to "advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation"⁷. The Wegovy label carries no such statement — its drug-interaction section covers insulin, hypoglycemia and delayed gastric emptying, and oral contraceptives do not appear in it⁸. If you rely on the pill, that is not a footnote; it is the most practical difference between these drugs for a woman who is not done having children, and we unpack it in GLP-1s and birth control.
• Pregnancy timing, which is not symmetrical. Both stop when a pregnancy is recognized, and weight loss is not recommended in pregnancy. But the planning advice differs, because the drugs clear at different speeds. The Zepbound label gives tirzepatide's elimination half-life as approximately 5 to 6 days and says only to discontinue when pregnancy is recognized⁷. The Wegovy label puts a number on the runway: discontinue at least two months before a planned pregnancy, expressly because of semaglutide's long half-life⁸. That is two more months of appetite returning before you are pregnant. On breastfeeding the labels are cautious rather than categorical — Wegovy tablets say breastfeeding is not recommended, both injections put it in a benefit-versus-risk judgment^7,8 — which is exactly why it belongs at the appointment before you start.

So — which is right for you?

The averages favor Zepbound. Averages are not mothers.

If you are done having children, tolerate injections and your plan covers it, the efficacy case for tirzepatide is the strongest thing in this article. If you take an oral contraceptive, the Zepbound label puts real work on you — four weeks of backup after starting and after every dose increase, which on a slow titration is most of a year. If you are planning a pregnancy, Wegovy's two-month runway is a genuine cost no efficacy number offsets. If needles are the obstacle, only one of these comes as a tablet. Pick a program that can adapt, then decide the molecule with a clinician who knows your history — not from a brand name on a billboard.